1999
Pneumococcal vaccines: history, current status, and future directions
Butler J, Shapiro E, Carlone G. Pneumococcal vaccines: history, current status, and future directions. The American Journal Of Medicine 1999, 107: 69-76. PMID: 10451012, DOI: 10.1016/s0002-9343(99)00105-9.Peer-Reviewed Original ResearchConceptsPneumococcal polysaccharide vaccinePolysaccharide vaccinePneumococcal infectionCertain underlying medical conditionsSerious pneumococcal diseaseCommunity-acquired pneumoniaPneumococcal conjugate vaccineUnderlying medical conditionsAnti-pneumococcal antibodiesLarger efficacy trialPrevention of infectionDrug-resistant strainsImmunocompetent childrenPneumococcal diseasePneumococcal vaccineBacterial meningitisConjugate vaccineCase fatalityDNA vaccineInvasive infectionsPneumococcal polysaccharideEfficacy trialsImmune responseMedical conditionsHigh risk
1998
Lyme Disease
Shapiro E. Lyme Disease. Pediatrics In Review 1998, 19: 147-154. PMID: 9584524, DOI: 10.1542/pir.19-5-147.Peer-Reviewed Original Research
1990
New Vaccines Against Haemophilus Influenzae Type b
Shapiro E. New Vaccines Against Haemophilus Influenzae Type b. Pediatric Clinics Of North America 1990, 37: 567-583. PMID: 2190140, DOI: 10.1016/s0031-3955(16)36905-x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsProtective efficacy of Haemophilus influenzae type b polysaccharide vaccine.
Shapiro E, Berg A. Protective efficacy of Haemophilus influenzae type b polysaccharide vaccine. Pediatrics 1990, 85: 643-7. PMID: 2179854, DOI: 10.1542/peds.85.4.643.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType b polysaccharide vaccineH influenzae type b polysaccharide vaccineHaemophilus influenzae type b polysaccharide vaccinePolysaccharide vaccineProtective efficacyMonths of ageVaccine failureInvasive diseaseH influenzae type b.Immunization Practices Advisory CommitteeH influenzae type bVaccine protective efficacyRandomized clinical trialsInfluenzae type bAvailable epidemiologic dataNormal serum concentrationsYears of ageTotal immunoglobulinSerum concentrationsImmune deficiencyClinical trialsEpidemiologic dataHemolytic complementVaccineChildren 18